The Trump administration is facing criticism from generic abortion pill manufacturer
GenBio on Tuesday urged the US District Court for the Western District of Louisiana to allow the company to intervene in the state’s litigation against the Food and Drug Administration over safety decisions around mifepristone. Rather than defend mifepristone’s safety record and the FDA’s past decisions, the Trump administration is merely echoing Louisiana’s criticisms and asking for the case to be paused while it conducts a new review ...
